Shuttle Pharmaceuticals (NASDAQ:SHPH) Issues Earnings Results

Shuttle Pharmaceuticals (NASDAQ:SHPH) announced its quarterly earnings results on Thursday. The company reported ($1.05) earnings per share (EPS) for the quarter, FiscalAI reports.

Shuttle Pharmaceuticals Price Performance

SHPH stock traded up $0.01 during midday trading on Friday, reaching $2.32. The company had a trading volume of 49,140 shares, compared to its average volume of 156,868. Shuttle Pharmaceuticals has a 1-year low of $2.22 and a 1-year high of $26.75. The stock has a 50 day moving average price of $3.56 and a 200-day moving average price of $4.03. The company has a market capitalization of $2.48 million, a price-to-earnings ratio of -0.05 and a beta of -1.01.

Analyst Upgrades and Downgrades

SHPH has been the subject of a number of research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a research note on Tuesday, October 14th. Wall Street Zen raised shares of Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, November 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Shuttle Pharmaceuticals presently has an average rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .